{"doc_id": "33631066", "type of study": "Therapy", "title": "", "abstract": "Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.\nCoronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels.\nThe use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies.\nData are needed from randomized, placebo-controlled trials.\nIn this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo.\nApproximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose.\nThe primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo.\nOf the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses.\nThe median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, -1.0; 95% CI, -2.5 to 0; P\u2009=\u20090.31 by the van Elteren test).\nIn the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group.\nMortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points; 95% CI, -7.6 to 8.2; nominal P\u2009=\u20090.94).\nIn this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.\n(Funded by F. Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.).\nCopyright \u00a9 2021 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 36}, {"term": "Severe Covid-19 Pneumonia", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 67}, {"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 158}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 75}, {"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 106}, {"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 56}, {"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 87}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia .", "Evidence Elements": {"Participant": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 36}, {"term": "Severe Covid-19 Pneumonia", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 67}], "Intervention": [{"term": "Tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Coronavirus disease 2019 ( Covid-19 ) is associated with immune dysregulation and hyperinflammation , including elevated interleukin-6 levels .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "The use of tocilizumab , a monoclonal antibody against the interleukin-6 receptor , has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies .", "Evidence Elements": {"Participant": [{"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 158}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 22, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "outcomes", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 115}], "Observation": [{"term": "better", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 106}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Data are needed from randomized , placebo-controlled trials .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this phase 3 trial , we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab ( at a dose of 8 mg per kilogram of body weight ) or placebo .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 75}, {"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 106}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 174, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Approximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 83, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 94, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 ( discharged or ready for discharge ) to 7 ( death ) in the modified intention-to-treat population , which included all the patients who had received at least one dose of tocilizumab or placebo .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical status", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 39}, {"term": "for discharge", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 120}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Of the 452 patients who underwent randomization , 438 ( 294 in the tocilizumab group and 144 in the placebo group ) were included in the primary and secondary analyses .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 78, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 107, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The median value for clinical status on the ordinal scale at day 28 was 1.0 ( 95 % confidence interval [ CI ] , 1.0 to 1.0 ) in the tocilizumab group and 2.0 ( non-ICU hospitalization without supplemental oxygen ) ( 95 % CI , 1.0 to 4.0 ) in the placebo group ( between-group difference , -1.0 ; 95 % CI , -2.5 to 0 ; P=0.31 by the van Elteren test ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 143, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 246, "end": 253, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "median value for clinical status on the ordinal scale at day 28", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 67}, {"term": "non-ICU hospitalization without supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 211}], "Observation": [{"term": "1.0", "negation": "negated", "UMLS": {}, "start": 72, "end": 75}, {"term": "2.0", "negation": "affirmed", "UMLS": {}, "start": 154, "end": 157}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "tocilizumab", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "1.0", "Outcome": "median value for clinical status on the ordinal scale at day 28", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "2.0", "Outcome": "median value for clinical status on the ordinal scale at day 28", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "2.0", "Outcome": "non-ICU hospitalization without supplemental oxygen", "Count": ""}]}, {"Section": "RESULTS", "Text": "In the safety population , serious adverse events occurred in 103 of 295 patients ( 34.9 % ) in the tocilizumab group and in 55 of 143 patients ( 38.5 % ) in the placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 111, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 49}], "Observation": [], "Count": [{"term": "103 of 295 patients ( 34.9 % )", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 92}, {"term": "55 of 143 patients (", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 145}]}, "Evidence Propositions": [{"Intervention": {"term": "tocilizumab", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "", "Count": "103 of 295 patients ( 34.9 % )", "Outcome": "serious adverse events"}]}, {"Section": "RESULTS", "Text": "Mortality at day 28 was 19.7 % in the tocilizumab group and 19.4 % in the placebo group ( weighted difference , 0.3 percentage points ; 95 % CI , -7.6 to 8.2 ; nominal P=0.94 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 49, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 81, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "Mortality", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 9}], "Observation": [{"term": "19.7 %", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 30}, {"term": "19.4 %", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 66}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "tocilizumab", "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, "Observation": "19.7 %", "Outcome": "Mortality", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "19.4 %", "Outcome": "Mortality", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia , the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days .", "Evidence Elements": {"Participant": [{"term": "hospitalized patients", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 56}, {"term": "severe Covid-19 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 87}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 112, "has_chemical": [{"text": "tocilizumab", "maps_to": "C1609165:tocilizumab", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "negated", "UMLS": {}, "start": 192, "end": 199, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical status", "negation": "negated", "UMLS": {}, "start": 152, "end": 167}, {"term": "mortality", "negation": "negated", "UMLS": {}, "start": 177, "end": 186}], "Observation": [{"term": "significantly better", "negation": "negated", "UMLS": {}, "start": 131, "end": 151}, {"term": "lower", "negation": "negated", "UMLS": {}, "start": 171, "end": 176}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "( Funded by F . Hoffmann-La Roche and the Department of Health and Human Services ; COVACTA ClinicalTrials.gov number , NCT04320615 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}